Our work helps change lives

Impact of Prostate Specific Antigen-Levels on Survival Outcomes with PROVENGE

• April 10, 2013
• Topics: Clinical Outcomes, Clinical Study, IMPACT, Phase 3 Post Hoc
• Published In: Urology Gold Journal

Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial

Survival Outcomes with PROVENGE in a Placebo-controlled, Randomized Phase 3 study

• July 29, 2010
• Topics: Clinical Outcomes, Clinical Study, IMPACT Phase 3
• Published In: New England Journal of Medicine

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Demonstration of PROVENGE-Activated Immune Cells Killing Other Cells that Have Prostate Cancer Antigens in vitro

• February 25, 2021
• Topics: Clinical Study, How Provenge Works, Phase 2, Post Hoc STAND
• Published In: Journal of the National Cancer Institute

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens

A Review Describing the Mechanism of Action of PROVENGE

• March 7, 2020
• Topics: How Provenge Works, Review Article
• Published In: Journal of the National Cancer Institute

Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T

PROVENGE Activation of Immune Function Is Related to Overall Survival in Patients with Advanced Prostate Cancer

• August 3, 2012
• Topics: Clinical Study, How Provenge Works, Phase 3 Post Hoc
• Published In: Cancer Immunology, Immunotherapy

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor Targeting Agen

• November 14, 2022
• Topics: Medicare, Real World Evidence

Treatment with PROVENGE^® in Medicare Beneficiaries with Advanced Prostate Cancer

• October 7, 2020
• Topics: Medicare, Real World Evidence
• Published In: Advances in Therapy

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer

Effects of Race on Real-World Outcomes with PROVENGE in Patients with Advanced Prostate Cancer

• February 28, 2020
• Topics: Clinical Study, Open Label, Post Hoc, PROCEED Real World Evidence
• Published In: Prostate Cancer and Prostatic Diseases

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

Real-World Outcomes with PROVENGE in Patients with Advanced Prostate Cancer 

• September 4, 2019
• Topics: Clinical Study, Open Label, PROCEED Real World Evidence
• Published In: American Cancer Society

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer